Immune
The Human Cathelicidin Antimicrobial Peptide LL-37 as a Potential Treatment for Polymicrobial Infected Wounds
McCrudden MT, McLean DT, Zhou M, et al. · Pharmaceutics · 2013
PMID: 23840194 · DOI: 10.3390/pharmaceutics5020525
Summary
In vitro characterization of LL-37 against gram-positive and gram-negative pathogens and biofilms relevant to polymicrobial wound infection. Endpoints: MIC, anti-biofilm activity, host-cell viability.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →LL-3737-residue human cathelicidin antimicrobial peptide studied in innate-immunity and wound-healing research.
Guides covering this compound
More Immune citations
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialCrit Care · 2013
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ · 2025
- Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialLiver · 1996